Skip to main navigation

Terms and Conditions

*

Client nav

About Arcturus

RNA Medicines

Technologies

Pipeline

Business Development

Publications

Investor Relations

Media Coverage

Categories

Year

Cystic Fibrosis News Today “ARCT-032, therapy for all with CF, showing safety i…

June 12, 2024

ENDPOINTS NEWS “Arcturus teases data from small trial of inhalable cystic fibro…

May 29, 2024

Nature Communications “Safety, immunogenicity and efficacy of the self-amplifyi…

May 14, 2024

Notice concerning Positive Results of Phase III Study of Bivalent Version of Ko…

March 19, 2024

MIT Technology Review “The next generation of mRNA vaccines is on its way”

February 2, 2024

BioPharm, International “Increasing mRNA Product Stability with Lyophilization”

January 31, 2024

Science Magazine “The First Self-Amplifying mRNA Vaccine”

January 25, 2024

Genetic Engineering & Biotechnology News “Self-Replicating RNA Manufacturer Cre…

January 18, 2024

Nature “Self-copying RNA vaccine wins first full approval: what’s next?”

December 6, 2023

San Diego Business Journal “Arcturus Lands $9M for Inhaled mRNA CF Treatment”

October 10, 2023

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 105

Arcturus-Covid19 Message.jpg

Nasdaq combined

Investor Home

Corporate Governance

Governance Highlights
Management Team
Board of Directors
Committee Composition

Financials & Filings

SEC Filings
Annual Reports
Quarterly Results

News & Events

Press Releases
Videos
Media Coverage
Presentations
Events

Stock Information

Stock Quote
Historical Price Lookup
Analyst Coverage

Investor Resources

Investor FAQ
Contact IR
Email Alerts

Home
Contact
Careers
Terms and Conditions
Privacy Policy

© 2024 Arcturus Therapeutics, Inc.

Search